• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ICON plc - Ordinary Shares (NQ:ICLR)

106.13 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ICON plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Ademi LLP Investigates Claims of Securities Fraud against ICON plc
February 26, 2026
From Ademi LLP
Via GlobeNewswire
News headline image
ICLR Investors Have Opportunity to Join ICON Public Limited Company Fraud Investigation with the Schall Law Firm
February 25, 2026
From Schall Law
Via GlobeNewswire
News headline image
ICLR INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving ICON Public Limited Company
February 24, 2026
From Kirby McInerney LLP
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ICON plc - ICLR
February 24, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
ICLR SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
February 19, 2026
From Kirby McInerney LLP
Via GlobeNewswire
News headline image
ICLR Investors Have Opportunity to Join ICON Public Limited Company Fraud Investigation with the Schall Law Firm
February 19, 2026
From The Schall Law Firm
Via Business Wire
News headline image
ICON INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating ICON plc on Behalf of ICON Stockholders and Encourages Investors to Contact the Firm
February 18, 2026
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
ICON PUBLIC LIMITED COMPANY INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
February 13, 2026
From Kirby McInerney LLP
Via Business Wire
News headline image
Securities Fraud Investigation Into ICON Public Limited Company (ICLR) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
February 13, 2026
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
ICON Public Limited Company (ICLR) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
February 13, 2026
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Securities Fraud Investigation Into ICON Public Limited Company (ICLR) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
February 12, 2026
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Rosen Law Firm Encourages ICON plc Investors to Inquire About Securities Class Action Investigation – ICLR
February 12, 2026
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
ICON plc Provides Update on Timing of Fourth Quarter and Full Year 2025 Earnings Results and Investigation into Accounting Practices
February 12, 2026
From ICON plc
Via Business Wire
News headline image
ICON’s Accellacare Site Network Expands Oncology Research Capabilities With New Cancer Institute Partnership
January 27, 2026
From ICON plc
Via Business Wire
News headline image
ICON 2025 global biotech survey solidifies China dominance and highlights opportunities for Western biotechs to stay competitive
December 09, 2025
From ICON plc
Via Business Wire
News headline image
ICON Survey Reveals Increasing Clinical Trial Startup Delays, Underscoring Need for Human-Centred Site Activation Solutions
December 02, 2025
From ICON plc
Via Business Wire
News headline image
ICON plc to Present at the Jefferies London Healthcare Conference
November 12, 2025
From ICON plc
Via Business Wire
News headline image
ICON Reports Third Quarter 2025 Results
October 22, 2025
From ICON plc
Via Business Wire
News headline image
ICON plc Schedules Third Quarter 2025 Earnings Conference Call
September 24, 2025
From ICON plc
Via Business Wire
News headline image
ICON Announces CEO Transition
September 04, 2025
From ICON plc
Via Business Wire
News headline image
ICON plc to Participate at Upcoming Investor Conferences
September 02, 2025
From ICON plc
Via Business Wire
News headline image
ICON Announces Results of Annual General Meeting
July 23, 2025
From ICON plc
Via Business Wire
News headline image
ICON Reports Second Quarter 2025 Results
July 23, 2025
From ICON plc
Via Business Wire
News headline image
ICON’s Leadership and Performance in Phase 1 Clinical Trials Recognised in Independent Industry Benchmarking Report
July 16, 2025
From ICON plc
Via Business Wire
News headline image
ICON and Its Employees Recognised as Clinical Research Industry Leaders, and for Innovation and Progress in Sustainability
July 07, 2025
From ICON plc
Via Business Wire
News headline image
ICON plc Schedules Second Quarter 2025 Earnings Conference Call
June 23, 2025
From ICON plc
Via Business Wire
News headline image
ICLR Investors Have Opportunity to Lead ICON Public Limited Company Securities Fraud Lawsuit with the Schall Law Firm
June 02, 2025
From The Schall Law Firm
Via Business Wire
News headline image
ICON plc to Present at the William Blair 45th Annual Growth Stock Conference
May 27, 2025
From ICON plc
Via Business Wire
News headline image
ICON releases its ICON Cares 2024 Report
May 19, 2025
From ICON plc
Via Business Wire
News headline image
Global ICON survey shows need for more efficient obesity clinical trial design to realise full potential of next-gen multi-indication therapies
May 07, 2025
From ICON plc
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap